Dako, an Agilent Technologies (A) company and a worldwide provider of cancer diagnostics, announced a new Master Collaboration Agreement with Amgen Inc. (AMGN). The financial details of the agreement were not disclosed.
The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular.
Dako said that the collaboration is important in the area of personalized medicine, where targeted treatments and companion diagnostics can help identify patients for whom a particular treatment may work, leading to improved patient care and more manageable healthcare costs.
Agilent's Dako business has partnerships with several top-tier pharma companies for the development of companion diagnostics.
For comments and feedback contact: editorial@rttnews.com
Business News